Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Myelodysplastic Syndrome
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(129)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Myelodysplastic Syndrome
No biomarker
Myelodysplastic Syndrome
decitabine/cedazuridine
Sensitive: A1 - Approval
decitabine / cedazuridine
Sensitive
:
A1
decitabine/cedazuridine
Sensitive: A1 - Approval
decitabine / cedazuridine
Sensitive
:
A1
No biomarker
Myelodysplastic Syndrome
No biomarker
Myelodysplastic Syndrome
luspatercept-aamt
Sensitive: A1 - Approval
luspatercept-aamt
Sensitive
:
A1
luspatercept-aamt
Sensitive: A1 - Approval
luspatercept-aamt
Sensitive
:
A1
Chr del(5q)
Myelodysplastic Syndrome
Chr del(5q)
Myelodysplastic Syndrome
lenalidomide
Sensitive: A1 - Approval
lenalidomide
Sensitive
:
A1
lenalidomide
Sensitive: A1 - Approval
lenalidomide
Sensitive
:
A1
No biomarker
Myelodysplastic Syndrome
No biomarker
Myelodysplastic Syndrome
azacitidine
Sensitive: A1 - Approval
azacitidine
Sensitive
:
A1
azacitidine
Sensitive: A1 - Approval
azacitidine
Sensitive
:
A1
No biomarker
Myelodysplastic Syndrome
No biomarker
Myelodysplastic Syndrome
decitabine
Sensitive: A1 - Approval
decitabine
Sensitive
:
A1
decitabine
Sensitive: A1 - Approval
decitabine
Sensitive
:
A1
PDGFRA rearrangement
Myelodysplastic Syndrome
PDGFRA rearrangement
Myelodysplastic Syndrome
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
IDH1 mutation
Myelodysplastic Syndrome
IDH1 mutation
Myelodysplastic Syndrome
ivosidenib
Sensitive: A1 - Approval
ivosidenib
Sensitive
:
A1
ivosidenib
Sensitive: A1 - Approval
ivosidenib
Sensitive
:
A1
CALR mutation
Myelodysplastic Syndrome
CALR mutation
Myelodysplastic Syndrome
luspatercept-aamt
Sensitive: A2 - Guideline
luspatercept-aamt
Sensitive
:
A2
luspatercept-aamt
Sensitive: A2 - Guideline
luspatercept-aamt
Sensitive
:
A2
CALR mutation
Myelodysplastic Syndrome
CALR mutation
Myelodysplastic Syndrome
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
SF3B1 mutation
Myelodysplastic Syndrome
SF3B1 mutation
Myelodysplastic Syndrome
luspatercept-aamt
Sensitive: A2 - Guideline
luspatercept-aamt
Sensitive
:
A2
luspatercept-aamt
Sensitive: A2 - Guideline
luspatercept-aamt
Sensitive
:
A2
RUNX1 mutation
Myelodysplastic Syndrome
RUNX1 mutation
Myelodysplastic Syndrome
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
SETBP1 mutation
Myelodysplastic Syndrome
SETBP1 mutation
Myelodysplastic Syndrome
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
CBL mutation
Myelodysplastic Syndrome
CBL mutation
Myelodysplastic Syndrome
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
NRAS mutation
Myelodysplastic Syndrome
NRAS mutation
Myelodysplastic Syndrome
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
ASXL1 mutation
Myelodysplastic Syndrome
ASXL1 mutation
Myelodysplastic Syndrome
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
SRSF2 mutation
Myelodysplastic Syndrome
SRSF2 mutation
Myelodysplastic Syndrome
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
TET2 mutation
Myelodysplastic Syndrome
TET2 mutation
Myelodysplastic Syndrome
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
ETNK1 mutation
Myelodysplastic Syndrome
ETNK1 mutation
Myelodysplastic Syndrome
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
STAT3 mutation
Myelodysplastic Syndrome
STAT3 mutation
Myelodysplastic Syndrome
eltrombopag + cyclosporin A microemulsion
Sensitive: A2 - Guideline
eltrombopag + cyclosporin A microemulsion
Sensitive
:
A2
eltrombopag + cyclosporin A microemulsion
Sensitive: A2 - Guideline
eltrombopag + cyclosporin A microemulsion
Sensitive
:
A2
No biomarker
Myelodysplastic Syndrome
No biomarker
Myelodysplastic Syndrome
eltrombopag + cyclosporin A microemulsion
Sensitive: A2 - Guideline
eltrombopag + cyclosporin A microemulsion
Sensitive
:
A2
eltrombopag + cyclosporin A microemulsion
Sensitive: A2 - Guideline
eltrombopag + cyclosporin A microemulsion
Sensitive
:
A2
TP53 mutation
Myelodysplastic Syndrome
TP53 mutation
Myelodysplastic Syndrome
APR-246
Sensitive: B - Late Trials
APR-246
Sensitive
:
B
APR-246
Sensitive: B - Late Trials
APR-246
Sensitive
:
B
No biomarker
Myelodysplastic Syndrome
No biomarker
Myelodysplastic Syndrome
ONO-7913
Sensitive: B - Late Trials
ONO-7913
Sensitive
:
B
ONO-7913
Sensitive: B - Late Trials
ONO-7913
Sensitive
:
B
DNMT3A mutation + SF3B1 mutation
Myelodysplastic Syndrome
DNMT3A mutation + SF3B1 mutation
Myelodysplastic Syndrome
lenalidomide
Resistant: B - Late Trials
lenalidomide
Resistant
:
B
lenalidomide
Resistant: B - Late Trials
lenalidomide
Resistant
:
B
No biomarker
Myelodysplastic Syndrome
No biomarker
Myelodysplastic Syndrome
MLN4924
Sensitive: B - Late Trials
MLN4924
Sensitive
:
B
MLN4924
Sensitive: B - Late Trials
MLN4924
Sensitive
:
B
No biomarker
Myelodysplastic Syndrome
No biomarker
Myelodysplastic Syndrome
lenalidomide
Sensitive: B - Late Trials
lenalidomide
Sensitive
:
B
lenalidomide
Sensitive: B - Late Trials
lenalidomide
Sensitive
:
B
Chr del(5)(q31)
Myelodysplastic Syndrome
Chr del(5)(q31)
Myelodysplastic Syndrome
lenalidomide
Sensitive: B - Late Trials
lenalidomide
Sensitive
:
B
lenalidomide
Sensitive: B - Late Trials
lenalidomide
Sensitive
:
B
No biomarker
Myelodysplastic Syndrome
No biomarker
Myelodysplastic Syndrome
MBG453
Sensitive: B - Late Trials
MBG453
Sensitive
:
B
MBG453
Sensitive: B - Late Trials
MBG453
Sensitive
:
B
No biomarker
Myelodysplastic Syndrome
No biomarker
Myelodysplastic Syndrome
venetoclax
Sensitive: B - Late Trials
venetoclax
Sensitive
:
B
venetoclax
Sensitive: B - Late Trials
venetoclax
Sensitive
:
B
No biomarker
Myelodysplastic Syndrome
No biomarker
Myelodysplastic Syndrome
KPT-8602
Sensitive: B - Late Trials
KPT-8602
Sensitive
:
B
KPT-8602
Sensitive: B - Late Trials
KPT-8602
Sensitive
:
B
TP53 mutation
Myelodysplastic Syndrome
TP53 mutation
Myelodysplastic Syndrome
decitabine/cedazuridine
Resistant: B - Late Trials
decitabine / cedazuridine
Resistant
:
B
decitabine/cedazuridine
Resistant: B - Late Trials
decitabine / cedazuridine
Resistant
:
B
TP53 mutation
Myelodysplastic Syndrome
TP53 mutation
Myelodysplastic Syndrome
CB-839
Sensitive: C2 – Inclusion Criteria
CB-839
Sensitive
:
C2
CB-839
Sensitive: C2 – Inclusion Criteria
CB-839
Sensitive
:
C2
FLT3 mutation
Myelodysplastic Syndrome
FLT3 mutation
Myelodysplastic Syndrome
ARO-002
Sensitive: C2 – Inclusion Criteria
ARO-002
Sensitive
:
C2
ARO-002
Sensitive: C2 – Inclusion Criteria
ARO-002
Sensitive
:
C2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login